Annovis Announces Closing of $21.0 Million Public Offering with 24% Contribution from the Board Chairman

Annovis expects the financing and existing cash to support operations through its March 2027 pivotal Alzheimer’s data readout.

Rhea-AI Summary

Annovis Bio (NYSE: ANVS) closed its $21.0 million underwritten public offering on November 6, 2026, with participation from its board chairman.

The chairman invested $5.00 million, approximately 24% of the offering. The offering generated approximately $21.0 million, excluding any proceeds from exercise of the accompanying warrants. Annovis expects net proceeds, together with existing cash, to fund uninterrupted operations through the pivotal Phase 3 Alzheimer’s study’s top-line data readout in March 2027 and continued clinical development of buntanetap in Alzheimer’s and Parkinson’s diseases.

4 points · 1 major

MixediHow this balance works

How this balance works

Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.

It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.

Rhea-AI Sentiment measures something else, the tone of the wording.

How the balance worksHow Sentiment works

1 major · 1 point

Hollow bars mark forward-looking points. How the balance works

Positive

• Major pointCompleted offering generated approximately $21.0 million, excluding proceeds from exercise of accompanying warrants. 58% of market cap
• Moderate point. Forward-looking: it has not happened yet and may not happen.Annovis expects proceeds and existing cash to fund uninterrupted operations through the March 2027 pivotal Alzheimer’s readout.
• Minor pointBoard chairman invested $5.00 million, approximately 24% of the offering.
• Minor point. Forward-looking: it has not happened yet and may not happen.Annovis expects funding to support continued buntanetap clinical development in Alzheimer’s and Parkinson’s diseases.

Negative

• Major point. Forward-looking: it has not happened yet and may not happen.Accompanying warrants create potential dilution if exercised.

News Explained

The November 6 closing’s $21.0 million offering amount equals 87.2 days of reported second-quarter operating cash outflow; the June 30, 2026 cash balance of $18,728,945 equals 77.8 days at that rate.

Sources and calculations

• Annovis public offering closing announcement (2026-11-09)
• Annovis second-quarter 2026 fundamentals (2026-06-30)

• Offering gross against the last reported quarterly operating outflow, in days at that rate $21,000,000 / ($21,913,620 / 91) = 87.2 days
• Available liquidity against the last reported quarterly operating outflow, in days at that rate $18,728,945 / ($21,913,620 / 91) = 77.8 days

Argus 15 min delay 6 alerts

+7.72% vs previous close $0.9101 last price 13.8x rel. volume Open Argus

Details

Market move: ANVS +7.72% vs previous close. $21.0 million offering closing

-7.7% Trough in 1 min

$0.83 – $0.99 Day Range

$39.15M Mkt Cap at Last Price

On Nov 9, the day this news came out, the latest delayed price for ANVS is 7.72% above the previous close. Argus tracked a trough of -7.7% from its starting point during tracking. Our momentum scanner has recorded 6 alerts for this stock so far that day. The latest delayed price is $0.91. Relative volume is exceptionally heavy at 13.8x what this stock usually trades by this time of day.

Data tracked by StockTitan Argus (15 min delayed). Upgrade to Gold for real-time data.

Key Figures

Offering proceeds: Approximately $21.0 million Chairman contribution: $5.00 million Share of offering: Approximately 24% +1 more

Offering proceeds

Approximately $21.0 million

Generated by the underwritten public offering, excluding proceeds from warrant exercises

Chairman contribution

$5.00 million

Contribution to the public offering

Share of offering

Approximately 24%

Chairman’s contribution as a portion of the offering

Expected funding runway

Through March 2027

Expected to fund operations through the pivotal Phase 3 Alzheimer’s data readout

Previous Offering Reports

1 past event · Latest: Nov 05

Same Type 1 event

1. Nov 05

   Offering pricing

   24h Move

   -44.7%

   Priced the same $21.0 million deal with share and warrant package terms before the announced closing.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

underwritten public offering, phase 3, top-line data readout

3 terms

underwritten public offering financial

"participated in the underwritten public offering and contributed $5.00 million"

An underwritten public offering is when a company sells new shares of its stock to the public with the help of a financial firm, called an underwriter. The underwriter agrees to buy all the shares upfront, reducing the company's risk, and then sells them to investors. This process helps companies raise money quickly and confidently from a wide range of buyers.

phase 3 medical

"a pivotal Phase 3 study of buntanetap in early AD"

Phase 3 is the late-stage clinical testing step for a new drug or medical treatment, where the product is given to large groups of patients to confirm effectiveness, monitor side effects, and compare it to standard care. Successful Phase 3 results are often the final scientific hurdle before regulators decide on approval and market launch—like passing a final exam before graduation—and can sharply change a company's valuation and future revenue prospects.

top-line data readout medical

"through the top-line data readout from the pivotal Phase 3 AD study"

A top-line data readout is the initial, high-level summary of a clinical trial’s main results, usually reporting whether primary endpoints were met and giving key safety signals without the full detailed analysis. For investors it matters because it delivers the first clear signal about a drug’s effectiveness or safety—like a score announced after a game—guiding expectations about regulatory progress, future studies, and potential commercial value.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

• Annovis Chairman of the Board invested $5.0 million as part of the underwritten public offering 
• Company expects cash to fund operations through the pivotal Phase 3 Alzheimer’s data readout in March 2027
  
  

MALVERN, Pa., Nov. 09, 2026 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a Phase 3 clinical-stage biotechnology company developing the investigational oral therapy, buntanetap, for neurodegenerative diseases such as Alzheimer’s disease (AD) and Parkinson’s disease (PD), today announced that its Chairman participated in the underwritten public offering and contributed $5.00 million, or approximately 24% of the $21.0 million offering, which closed on November 6, 2026.

“A significant contribution like this shows strong faith and confidence in our drug and its development,” said Maria Maccecchini, Ph.D., Founder, President and CEO of Annovis. “We have spent years building this program with the interests of our shareholders and patients in mind. This financing allows us to reach the data readout of our pivotal Phase 3 study of buntanetap in early AD in March 2027, a milestone our entire team is excited about and fully committed to delivering.”

The offering generated approximately $21.0 million, excluding any proceeds from the exercise of the accompanying warrants. Together with existing cash, the net proceeds are expected to fund operations without interruption through the top-line data readout from the pivotal Phase 3 AD study and the continued clinical development of buntanetap in AD and PD.

Full terms of the offering can be found in the Company’s SEC filings.

About Annovis
Headquartered in Malvern, Pennsylvania, Annovis Bio, Inc. (NYSE: ANVS) is a Phase 3 clinical-stage biotechnology company developing treatments for neurodegenerative diseases such as Alzheimer's disease (AD) and Parkinson's disease (PD). The Company's lead drug candidate, buntanetap (formerly posiphen), is an investigational once-daily oral therapy that inhibits the translation of multiple neurotoxic proteins, including APP and amyloid beta, tau, alpha-synuclein, and TDP-43, through a specific RNA-targeting mechanism of action. By addressing the underlying causes of neurodegeneration, Annovis aims to halt disease progression and improve cognitive and motor functions in patients. For more information, visit www.annovisbio.com and follow us on LinkedIn, YouTube, and X.

Investor Alerts
Interested investors and shareholders are encouraged to sign up for press releases and industry updates by registering for email alerts at https://www.annovisbio.com/email-alerts.

Forward-Looking Statements
This press release contains forward-looking statements under the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended. Actual results may differ due to various risks and uncertainties, including those outlined in the Company’s SEC filings under “Risk Factors” in its Annual Report on Form 10-K and Quarterly Reports on Form 10-Q. The Company undertakes no obligation to update forward-looking statements except as required by law.

Contact Information:
Annovis Bio Inc.
101 Lindenwood Drive
Suite 225
Malvern, PA 19355
www.annovisbio.com

Investor Contact:
Alexander Morin, Ph.D.
Director, Strategic Communications
Annovis Bio
ir@annovisbio.com

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How much did Annovis raise, and how much did its chairman invest?

The offering generated approximately $21.0 million, excluding proceeds from exercise of accompanying warrants. The board chairman contributed $5.00 million, approximately 24% of the offering, which closed on November 6, 2026.

How long does Annovis expect its cash to fund operations after the offering?

Annovis expects net proceeds and existing cash to fund operations without interruption through the pivotal Phase 3 Alzheimer’s study’s top-line data readout in March 2027. The funding is also expected to support continued clinical development of buntanetap in Alzheimer’s and Parkinson’s diseases.